Very recently, in 2018, the latest guidelines from the National Institute on Aging and the Alzheimer’s Association (NIA-AA) set out a research framework approach towards AD diagnosis, which consists of Aβ deposition (A), tau pathology (T), and neurodegeneration or neuronal injury (N) [6]. The gene discussed is MAPT; the disease is Alzheimer disease.